Pfizer's Tukysa (tucatinib) wins a breast cancer maintenance approval after delaying progression, while MimiVax's SurVaxM misses its overall glioblastoma survival goal despite a younger-patient signal. Halozyme reports an injunction against subcutaneous Keytruda (pembrolizumab) in eight European markets; Caribou said yesterday it plans to halt its two donor CAR-T programs amid financing pressure. Cerevance's investigational solengepras cuts Parkinson's off time by 37 minutes a day beyond placebo. Novartis reports FDA approval of Rhapsido (remibrutinib) for adults with symptomatic dermographism inadequately controlled by H1 antihistamines.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →